Strong Balance SheetA dramatic increase in equity ratio and sharply reduced leverage materially lowers financial risk and enhances resilience. This stronger capital base gives the company durable flexibility to fund operations, absorb shocks, pursue organic growth, and reduce financing costs over the next several quarters.

Revenue And Margin ExpansionSustained revenue growth alongside improving net profit margins indicates scalable operations and improved cost controls. This combination supports durable earnings power, better internal funding for R&D/capex, and competitive positioning in the API market over the medium term.

Improving Cash GenerationConversion of earnings into positive free cash flow signals operational strength and improves financial flexibility. Positive FCF supports deleveraging, reinvestment, and working capital needs, enabling more sustainable capital allocation decisions across upcoming quarters.

Bears Say

Free Cash Flow VolatilityAlthough FCF is now positive, historical swings in free cash flow suggest unstable investment or working capital patterns. Persistent volatility can constrain reliable funding for capex, debt repayments, or dividend policy and may force costly external financing during adverse periods.

Modest EPS GrowthSingle-digit EPS growth points to moderate earnings momentum relative to high-growth peers. If future EPS expansion remains modest, the company may face limits on reinvestment capacity and slower long-term shareholder returns absent additional margin or market-share improvements.

Limited Customer/geography DisclosureLack of disclosure on major customers and revenue mix obscures concentration and market risks. Hidden customer or geographic dependence can create structural vulnerability to demand, pricing, or regulatory shocks and complicates assessment of sustainable revenue streams.

Supriya Lifescience Limited News

Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results

An announcement from Supriya Lifescience Limited ( ($IN:SUPRIYA) ) is now available. Supriya Lifescience Limited has announced the...

2M ago

Supriya Lifescience Schedules Earnings Call to Discuss Financial Performance

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has issued an announcement. Supriya Lifescience Limited has announced an upcoming earnings...

4M ago

SUPRIYA FAQ

What was Supriya Lifescience Limited’s price range in the past 12 months?

Supriya Lifescience Limited lowest stock price was ₹556.85 and its highest was ₹841.70 in the past 12 months.

What is Supriya Lifescience Limited’s market cap?

Supriya Lifescience Limited’s market cap is ₹55.56B.

When is Supriya Lifescience Limited’s upcoming earnings report date?

Supriya Lifescience Limited’s upcoming earnings report date is Jun 02, 2026 which is in 99 days.

How were Supriya Lifescience Limited’s earnings last quarter?

Supriya Lifescience Limited released its earnings results on Feb 09, 2026. The company reported ₹6.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.2.

Is Supriya Lifescience Limited overvalued?

According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Supriya Lifescience Limited pay dividends?

Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.13%. See more information on Supriya Lifescience Limited dividends here

What is Supriya Lifescience Limited’s EPS estimate?

Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Supriya Lifescience Limited have?

Supriya Lifescience Limited has 80,482,800 shares outstanding.

What happened to Supriya Lifescience Limited’s price movement after its last earnings report?

Supriya Lifescience Limited reported an EPS of ₹6.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.803%.

Which hedge fund is a major shareholder of Supriya Lifescience Limited?

Currently, no hedge funds are holding shares in IN:SUPRIYA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Supriya Lifescience Limited

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.